Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 14.71% is 65% above its 5-year average of 8.93%, near the high end of its 5-year range (-141.46%–32.10%).
136.30% above its 12-month average of -40.53%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -108.16%.
EBITDA MARGIN
14.71%
EBITDA MARGIN AVG TTM
-40.53%
EBITDA MARGIN AVG 3Y
7.23%
EBITDA MARGIN AVG 5Y
8.93%
EBITDA MARGIN AVG 10Y
5.02%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+136.30%
CURRENT VS 3Y AVG
+103.36%
CURRENT VS 5Y AVG
+64.69%
CURRENT VS 10Y AVG
+192.89%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Organogenesis Holdings Inc.
Market Cap
$172.42M
EBITDA Margin
14.71%
TTM Avg
-40.53%
3Y Avg
7.23%
5Y Avg
8.93%
Market Cap
$174.46M
EBITDA Margin
-5219.12%
TTM Avg
-6964.15%
3Y Avg
-7000.85%
5Y Avg
-5161.09%
Market Cap
$171.13M
EBITDA Margin
-144.16%
TTM Avg
-87.79%
3Y Avg
-115.19%
5Y Avg
-149.65%
Market Cap
$174.29M
EBITDA Margin
-258.92%
TTM Avg
-202.75%
3Y Avg
-649.71%
5Y Avg
-1766.39%
Market Cap
$169.53M
EBITDA Margin
-6.19%
TTM Avg
-12.15%
3Y Avg
-13.37%
5Y Avg
-13.97%
Market Cap
$169.43M
EBITDA Margin
-138.09%
TTM Avg
-113.30%
3Y Avg
-81.67%
5Y Avg
-67.39%
Market Cap
$168.10M
EBITDA Margin
-83.89%
TTM Avg
-252.72%
3Y Avg
-1380.70%
5Y Avg
-1383.45%
Market Cap
$165.63M
EBITDA Margin
-18889.15%
TTM Avg
-9445.90%
3Y Avg
-9445.90%
5Y Avg
-9445.90%
Market Cap
$179.26M
EBITDA Margin
-748.35%
TTM Avg
-748.35%
3Y Avg
-1092.82%
5Y Avg
-1042.94%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Organogenesis Holdings Inc. (ORGO) | $172.42M | 14.71% | -40.53% | 7.23% | 8.93% |
| Yarrow Bioscience Inc (YARW)vs › | $174.46M | -5219.12% | -6964.15% | -7000.85% | -5161.09% |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | -144.16% | -87.79% | -115.19% | -149.65% |
| ProQR Therapeutics N.V. (PRQR)vs › | $174.29M | -258.92% | -202.75% | -649.71% | -1766.39% |
| Journey Medical Corporation (DERM)vs › | $169.53M | -6.19% | -12.15% | -13.37% | -13.97% |
| MediWound Ltd. (MDWD)vs › | $169.43M | -138.09% | -113.30% | -81.67% | -67.39% |
| Cue Biopharma, Inc. (CUE)vs › | $168.10M | -83.89% | -252.72% | -1380.70% | -1383.45% |
| Nkarta, Inc. (NKTX)vs › | $165.63M | -18889.15% | -9445.90% | -9445.90% | -9445.90% |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | -748.35% | -748.35% | -1092.82% | -1042.94% |
| OptimizeRx Corp. (OPRX)vs › | $165.51M | 14.98% | 2.40% | -11.30% | -6.96% |
Gross Margin
67.6%
EBITDA Margin
14.7%
Operating Margin
9.9%
Net Margin
-19.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -108.16% |
| 2026-03-31 | -141.46% |
| 2025-12-31 | 32.10% |
| 2025-09-30 | 19.03% |
| 2025-06-30 | -4.14% |
| 2025-03-31 | -16.03% |
| 2024-12-31 | 11.58% |
| 2024-09-30 | 9.24% |
| 2024-06-30 | -7.44% |
| 2024-03-31 | 0.11% |
| 2023-12-31 | 11.06% |
| 2023-09-30 | 12.80% |
| 2023-06-30 | 11.25% |
| 2023-03-31 | -0.07% |
| 2022-12-31 | 11.49% |
| 2022-09-30 | 3.81% |
| 2022-06-30 | 12.10% |
| 2022-03-31 | 2.51% |
| 2021-12-31 | 19.66% |
| 2021-09-30 | 18.46% |
| 2021-06-30 | 22.18% |
| 2021-03-31 | 15.60% |
| 2020-12-31 | 22.44% |
| 2020-09-30 | 24.98% |
| 2020-06-30 | -0.79% |
| 2020-03-31 | -21.65% |
| 2019-12-31 | 0.80% |
| 2019-09-30 | -9.25% |
| 2019-06-30 | -7.64% |
| 2019-03-31 | -17.02% |
| 2018-12-31 | -6.80% |
| 2017-12-31 | -19.71% |
| 2016-12-31 | 291.66% |
